BlossomHill Joins Guggenheim Healthcare Conference
The San Diego biopharmaceutical company will present at the event and host a fireside chat on November 10, 2026.
Updated on Nov. 3, 2026 in Biotech
BlossomHill Therapeutics, a Nasdaq-listed clinical-stage biopharmaceutical company (ticker BLSM), announced its participation in Guggenheim's 3rd Annual Healthcare Innovations Conference at the Intercontinental Boston. Management will take part in a fireside chat and one-on-one investor meetings.
Why it matters
The participation gives investors and analysts a direct opportunity to hear from management of a San Diego-headquartered drug developer. The company's lead clinical program is an investigational therapy for EGFR-mutant non-small cell lung cancer.
The fireside chat is scheduled for November 10, 2026, at 3:00 pm Eastern Time and can be accessed by audio webcast on the company's website, with an archived replay available for 90 days. The announcement does not disclose what topics management will address during the discussion.
The players
BlossomHill Therapeutics, Inc.
A Nasdaq-listed clinical-stage biopharmaceutical company headquartered in San Diego and developing targeted therapies for cancer.
Guggenheim Securities
The investment bank that hosts the annual Healthcare Innovations Conference connecting public healthcare companies with institutional investors.
J. Jean Cui, Ph.D.
The founder and leader of BlossomHill Therapeutics, whose previous work includes development of three FDA-approved oncology drugs.
The details
BlossomHill management will participate in one-on-one investor meetings alongside the fireside chat at Guggenheim's 3rd Annual Healthcare Innovations Conference in Boston. The company's lead clinical program is BH-30643, an investigational OMNI-EGFR inhibitor that has received Fast Track designation for the C797S resistance population after third-generation EGFR TKI treatment.
Timeline
November 3, 2026: BlossomHill announces conference participation.
November 10, 2026, 3:00 pm ET: Fireside chat at the Guggenheim conference.
90 days after the fireside chat: Archived replay remains available.
Biotech Investor Access
Annual investor conferences such as Guggenheim's Healthcare Innovations series serve as a recurring venue where clinical-stage biotechs present pipelines to institutional investors. BlossomHill's appearance at the third edition places it among companies seeking capital for oncology programs in a sector that depends heavily on these forums.
Readers interested in BlossomHill's lung cancer program can listen to the fireside chat live by audio webcast on the company's Events & Presentations page. The archived replay will remain accessible for 90 days, allowing review after the event.
The takeaway
Investor conferences give clinical-stage companies a structured chance to explain their pipelines beyond press releases. Readers tracking BlossomHill can use the scheduled webcast and archived replay to follow its lung cancer program directly.
What happens next
BlossomHill management's fireside chat is scheduled for November 10, 2026, at 3:00 pm Eastern Time, with an archived replay available for 90 days afterward.
Further reading
Explore more Biotech coverage to see how clinical-stage drug developers are advancing their oncology pipelines.
